Menarini And Radius Skip Into SERD Lead With Elacestrant Success

Breast Cancer Therapy Improves PFS In Phase III EMERALD Trial

 
• By Kevin Grogan

Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.

emerald
Elacestrant sparkles in emerald • Source: Alamy

While a number of oral SERD (selective estrogen receptor degrader) breast cancer drugs are moving closer to the market, Menarini Groupand partner Radius Health, Inc. have moved ahead of the pack with promising late-stage data for elacestrant.

The partners have announced positive topline progression-free survival (PFS) results from the Phase III EMERALD trial for elacestrant, their SERD...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip